RSS Feeds

RSS feeds are used for sharing and syndicating content from a web site which is regularly updated. You can subscribe to and view RSS feeds using an RSS reader or some email clients.

News and Announcements

The recent news and announcement feeds provide the latest news items published by Clinuvel.

Latest Company News Items (RSS)

Clinuvel Multimedia

The multimedia feeds provide the latest video, audio and blog items published by Clinuvel.

Webcasts (RSS)

Blog Posts - All Categories (RSS)

Research and Knowledgebase

The multimedia feeds provide the latest video and audio items published by Clinuvel.

Science of Skin

Clinuvel Blog Posts

Inside Clinuvel: Rare diseases day 2013 - rare disea...

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

Q&A: SCENESSE® successful in Phase IIa vitiligo...

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Inside Clinuvel: Vitiligo and the “Michael Jackson...

I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

Read More

Clinuvel Webcasts

What can vitiligo patients do? – Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

The future of vitiligo treatment – Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Vitiligo trials of SCENESSE® – Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Clinuvel Spotlight

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more